Why pharmacoeconomic policy should be transnational

Pharmaceuticals Policy and Law

Volumn 14, Issue 1, 2012, Pages 7-16

  Abraham, Ivo ^a,b   Bootman, J Lyle ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b Matrix45   (United States)

Author keywords

cluster analysis; Pharmacoeconomics; policy

Indexed keywords

ARTICLE; CLUSTER ANALYSIS; DECISION MAKING; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE POLICY; INTERNATIONAL COOPERATION; PHARMACOECONOMICS; PRIORITY JOURNAL;

EID: 84856862958     PISSN: 13892827     EISSN: 2210495X     Source Type: Journal    
DOI: 10.3233/PPL-2011-0338     Document Type: Article

References (4)

1. OECD Health Data 2010: Statistics and Indicators (CD-ROM). Paris, OECD 2010.Available at http://www.oecdbookshop.org/oecd/display.asp?CID= oecd&LANG=en&SF1=DI&ST1=5KMHCVM69 T45 (last accessed 18 June 2011).
2. J.L. Bootman, R.J. Townsend and W.F. McGhan, Introduction to pharmacoeconomic analysis, in: Principles of Pharmacoeconomics (3rd ed.), J.L. Bootman, R.J. Townsend and W.F. McGhan, eds, Cincinnati, OH: Harvey Whitney, 2005.
3. B.S. Everitt, S. Landau, M. Leese and D. Stahl, Cluster Analysis (5th ed.), Chichester (UK): Wiley.
4. See p. 51 and pp. 109-111 in: International Trade Administration. Pharmaceutical Price Controls in OECD Countries: Implications for U.S. Consumers, Pricing, Research and Development, and Innovation. Washington, DC (USA): U.S. Department of Commerce, 2004. Available at http://www.ita.doc.gov/ td/chemicals/drugpricingstudy.pdf. Last accessed 18 June 2011.